Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

Inclusion Criteria: Each patient was to have met all of the following inclusion criteria to be enrolled in the study: * 18 years of age or older * Diagnosis of relapsing-remitting multiple sclerosis (RRMS) * An Expanded Disability Status Score (EDCC) of 0 to 5.5, inclusive * Be willing and able to comply with the protocol for the duration of the study period * Be willing to use adequate "double-barrier" contraceptive methods for the duration of the study period * If female, must be neither pregnant or breast-feeding * Written informed consent * To be enrolled in the treatment phase of the study each patient must have a total of at least 2 new gadolinium-diethylenetriamine pentaacetic acid (Gd)-enhancing lesions seen over the series of 3 pretreatment magnetic resonance imaging (MRI)s. Exclusion Criteria: Patients meeting any of the following exclusion criteria were not to be enrolled in the study: * Diagnosis of primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) * Received any investigational drug or experimental procedure within 3 months prior to study day 0 * If the patient has received disease-modifying treatments they must be discontinued prior to study day 0 as follows: 1. Cyclophosphamide or mitoxantrone- 6 months prior 2. Interferons, glatiramer acetate and azathioprine- 12 weeks prior 3. Methotrexate, IV immunoglobulin, cyclosporin, plasma exchange or corticosteroids- 8 weeks prior * Never have been exposed to Tysabri® (natalizumab)or any other VLA-4 (α4β1)antagonist * Have an active infection or be considered to be at high risk for developing an infection * Have a history of hepatitis B, C or human immunodeficiency virus (HIV) * Have a chest X-ray within 6 months of study day 0 with clinically significant findings or abnormalities * Have inadequate renal or hepatic function * Have a known history of cancer, except for distant history (\>10 years) of carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin * Received any live, attenuated vaccinations within 30 days prior to study day 0 * Have a history of illicit drug or alcohol abuse within 5 years of study day 0 * Have a history of hypersensitivity to prior monoclonal antibody (mAb) treatment * Have a history of allergy or sensitivity to Gd * Have a history that would preclude serial MRI scans